

# REGENICIN, INC.

## FORM 8-K (Current report filing)

Filed 11/10/10 for the Period Ending 11/10/10

Address	10 HIGH COURT LITTLE FALLS, NJ 07424
Telephone	646-403-3581
CIK	0001412659
Symbol	RGIN
SIC Code	3564 - Industrial and Commercial Fans and Blowers and Air Purification Equipment
Industry	Biotechnology & Drugs
Sector	Healthcare
Fiscal Year	09/30

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): November 10, 2010

Regenicin, Inc

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction of incorporation)

333-146834

(Commission File Number)

27-3083341

(I.R.S. Employer Identification No.)

10 High Court, Little Falls, NJ

(Address of principal executive offices)

07424

(Zip Code)

Registrant's telephone number, including area code: 212 518-8474

470 Park Avenue South 16th Floor, New York, NY 10010

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

## Section 8 – Other Events

### Item 8.01 Other Events

On November 10, 2010, we issued a press release announcing our new symbol on the OTC Bulletin Board Market. The new for our company is **RGIN**.

A copy of the press release issued in connection with this announcement is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference.

## Section 9 – Financial Statements and Exhibits

### Item 9.01 Financial Statements and Exhibits

<u>Exhibit</u>	<u>Description</u>
----------------	--------------------

<u>No.</u>	
------------	--

99.1	Press release of Regenicin, Inc., dated November 10, 2010
------	---

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Regenicin, Inc**

/s/ Randall McCoy  
Randall McCoy

Date: **November 10, 2010**

## **Regenicin Changes Its Ticker Symbol to RGIN.OB**

(New York, NY) – November 10, 2010 – Regenicin, Inc. (OTC Bulletin Board: WDST), a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs, today announced the change of its ticker symbol on the OTC Bulletin Board from "WDST" to "RGIN.OB" effective at the opening of the market on Wednesday, November 10, 2010.

Regenicin CEO, Randall McCoy said the change in ticker symbol was made to better represent the company's name and future goals in advancing the field of regenerative medicine.

### **About Regenicin**

Regenicin, Inc. is a development stage biotechnology company. Regenicin is a publicly traded company, with headquarters in New York. Additional information can be found in the company's filings with the Securities and Exchange Commission located at [www.sec.gov](http://www.sec.gov).

### **Safe Harbor Statement**

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Regenicin(TM), Inc.